PREVENT（Warfarin）研究PPT课件.pptVIP

Prevention of Recurrent Venous Thromboembolism PREVENT Trial: Composite Endpoint PREVENT Trial PREVENT: Conclusions Among patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for six months, treatment with low-intensity warfarin (target INR, 1.5-2.0) was associated with a reduction in recurrent venous thromboembolism and in the composite of recurrent venous thromboembolism, major hemorrhage, or death during follow-up No significant excess major bleeding occurred in the warfarin arm First randomized trial to examine the use of low-intensity war